Natrecor
Evidence Grade B — Strong clinical evidence. 563 published studies, 504 human. 280 registered clinical trials.
Nesiritide (previously sold as Natrecor) is a recombinant form of BNP — a hormone naturally released by the heart when it is under stress from fluid overload. It was previously approved for acute heart failure but was withdrawn from the US market in 2020. Its story is a cautionary tale about how early enthusiasm can be reversed by rigorous outcomes data.
563 published studies: 504 human, 9 animal, 2 in-vitro, 199 reviews
Nesiritide was marketed as Natrecor (approved August 2001) for acute decompensated heart failure. The NDA was withdrawn in June 2020. It was widely adopted after initial approval but came under significant scrutiny following a 2005 analysis that raised concerns about potential increases in mortality and kidney damage.
The large ASCEND-HF trial (over 7,000 patients) subsequently showed that nesiritide provided only modest symptom relief over standard diuretics, with no mortality benefit and a signal toward increased low blood pressure episodes. These results, combined with the earlier safety concerns and the availability of effective alternatives, led to its commercial withdrawal. Nesiritide illustrates how early enthusiasm for a biologically logical therapy can be tempered by rigorous outcomes data.
BNP is the heart's natural distress signal when it is overloaded with fluid. Nesiritide mimics this signal by activating natriuretic peptide receptors, which causes blood vessels to dilate (reducing the workload on the heart), promotes sodium and water excretion by the kidneys (reducing fluid overload), and suppresses the hormonal systems that drive fluid retention. These combined effects rapidly reduce the pressure and volume burden on a failing heart.
Nesiritide was widely adopted after its initial approval and reached over $700 million in peak sales. However, a 2005 analysis raised concerns about potential increases in mortality and kidney damage. The definitive ASCEND-HF trial (over 7,000 patients) subsequently showed that nesiritide provided only marginal symptom relief over standard diuretics, with no mortality benefit — making its high cost unjustifiable. The drug's trajectory from rapid uptake to meta-analysis concerns to a landmark negative trial to market withdrawal is a textbook case study in evidence-based medicine. Interestingly, the natriuretic peptide pathway was later validated through sacubitril/valsartan (Entresto), which raises endogenous natriuretic peptides through enzyme inhibition rather than injecting them directly.
Natriuretic Peptides and Metabolic Risk in Obesity
An Efficacy and Safety Study for Nesiritide in Heart Failure Patients With Reduced Kidney Function Undergoing Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass (CPB Pump or Heart Lung Machine)
Boston Medical Center Ultrasound Decongestion Study in Heart Failure
Recombinant Human Brain Natriuretic Peptide for the Recovery Stage of Septic Shock
Prospective Evaluation of AI-ECG for SHD Detection
Health Canada Market Authorisation
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Exenatide was the first GLP-1 receptor agonist approved anywhere, reaching the market as Byetta in April 2005. The once-weekly formulation Bydureon followed in 2012. Clinical trials showed blood sugar reductions (HbA1c) of 1.6–1.9% and modest weight loss of 2–4 kg. The EXSCEL cardiovascular outcomes trial, involving over 14,700 patients, showed a trend toward cardiovascular benefit but narrowly missed statistical significance. While exenatide was groundbreaking as the first in its class, it has been largely overtaken by newer GLP-1 treatments that offer greater efficacy, less frequent dosing, and proven cardiovascular benefits. It remains available and in clinical use, particularly in combination products.
Lixisenatide was marketed as Adlyxin in the US (approved July 2016), though it has since been discontinued in the US market. The ELIXA cardiovascular trial, involving over 6,000 patients, was the first cardiovascular outcomes trial for any GLP-1 medication to report results. It showed a neutral cardiovascular profile — neither harmful nor beneficial — meeting safety requirements but not demonstrating the heart benefits later shown by semaglutide and liraglutide. Lixisenatide found its primary clinical role in combination with basal insulin, marketed as Soliqua (lixisenatide plus insulin glargine). This combination addresses both fasting blood sugar (via insulin) and post-meal spikes (via lixisenatide) in a single daily injection. As a standalone treatment, it has been largely superseded by more potent GLP-1 medications.
Pramlintide is marketed as Symlin (approved March 2005) and remains the only approved amylin-based treatment. It is used alongside mealtime insulin in both type 1 and type 2 diabetes. Clinical trials showed modest blood sugar improvements (HbA1c reductions of 0.2–0.6%) and approximately 2.3 kg of weight loss — less dramatic than GLP-1 treatments but meaningful as an add-on therapy. Symlin carries a boxed warning for severe hypoglycaemia, particularly when combined with insulin, and requires careful dose adjustment. Practical uptake has been limited by the need for separate injections at each meal alongside existing insulin injections. Despite its modest clinical impact, pramlintide remains the only medication that addresses the amylin deficiency in diabetes, filling a distinct biological role that GLP-1 treatments do not cover.
